March 2011: CPR Pharma Services is supporting research in Australia with the launch of its research services capability. By utilizing our state of the art mass spectrometry capability and considerable expertise, CPR are solving problems in research that are unblocking clinical research activity across Australia.  As a result of the research and development conducted to solve these complex assay problems, we see an enhancement of CPR’s reputation globally, which has already translated into several new clients, including large pharma, interested in our unique capabilities.

 

January 2011: CPR Pharma Services raises $400K from existing investors to add Immunoassay Capability to its existing suite of tandem mass spectrometry services.  The Immunoassay Capability is expected to be fully operational in Q3 2011.

 

November 2010: CPR Pharma Services purchased a 4^th API 4000 tandem mass spectrometer to become the best resourced GLP tandem mass spectrometry laboratory in Australia.  This allows CPR to provide unparalleled assay support for clinical trials in Australia.